Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bioventix Plc | BVXP | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 3,750.00 | 08:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3,750.00 | 3,750.00 | 3,750.00 | 3,750.00 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 28/10/2024 | Interim | GBP | 0.87 | 07/11/2024 | 08/11/2024 | 21/11/2024 |
| 25/03/2024 | Interim | GBP | 0.68 | 11/04/2024 | 12/04/2024 | 26/04/2024 |
| 30/10/2023 | Interim | GBP | 0.9 | 09/11/2023 | 10/11/2023 | 24/11/2023 |
| 27/03/2023 | Interim | GBP | 0.62 | 06/04/2023 | 11/04/2023 | 21/04/2023 |
| 24/10/2022 | Interim | GBP | 0.74 | 03/11/2022 | 04/11/2022 | 18/11/2022 |
| 24/10/2022 | Special | GBP | 0.26 | 03/11/2022 | 04/11/2022 | 18/11/2022 |
| 28/03/2022 | Interim | GBP | 0.52 | 07/04/2022 | 08/04/2022 | 22/04/2022 |
| 18/10/2021 | Interim | GBP | 0.62 | 28/10/2021 | 29/10/2021 | 12/11/2021 |
| 18/10/2021 | Special | GBP | 0.38 | 28/10/2021 | 29/10/2021 | 12/11/2021 |
| 29/03/2021 | Interim | GBP | 0.43 | 08/04/2021 | 09/04/2021 | 23/04/2021 |
| 19/10/2020 | Interim | GBP | 0.52 | 29/10/2020 | 30/10/2020 | 13/11/2020 |
| 19/10/2020 | Special | GBP | 0.53 | 29/10/2020 | 30/10/2020 | 13/11/2020 |
| 30/03/2020 | Interim | GBP | 0.36 | 09/04/2020 | 14/04/2020 | 28/04/2020 |
| Top Posts |
|---|
Posted at 29/10/2024 06:48 by multibagger Good morning all :)My post has landed badly - unfortunate. I understand the science and can see where tech in this area is heading and invest with 5-10 year timeframes at a minimum unless the story changes. Though antibodies will have their niche role they will diminish in importance, there is a potential Eastman Kodak v digital, video cassette v digital streaming moment here. Some may prefer not to see what is coming and what was a cash cow could stagnate or diminish - investing is about looking forwards. I am not here to try and persuade you to invest anywhere :) I have got into APTA fairly recently, so looking at their historical share price at 117p is immaterial to my investment decision. Good luck and we can take stock in about 3-5 years time as to the relative share prices of BVXP and APTA if the AIM market still exists and we are all around. I wish you well - investing is not a zero sum game but an infinite one. We make our choices and decide what to buy and when to exit. A note from a very successful, happy and cheerful dimwit :) |
Posted at 25/10/2024 08:35 by sharesoc Join ShareSoc on the 27th November, in London, for a Growth Company Seminar featuring presentations from: Bioventix (BVXP) presented by Peter Harrison, CEO; Resolute Mining (RSG) presented by Terry Holohan, MD & CEO; and Altona Rare Earths (REE) presented by Dr. Cedric Simonet, CEO. The presentations will begin at 5 pm; each company will present for 25 minutes, followed by a 15-minute Q&A session. There will be a chance to network over drinks and a buffet after the presentations. Attend in-person or watch virtually.Find out more and register here: |
Posted at 13/9/2024 12:51 by melody9999 Sharw 1583 re communication that has always been the case. But in the last few weeks I think the possible Budget changes to IHT AIM and CGT increases have caused the share price retrace.BVXP is perhaps the best example of a great AIM share that has a large proportion of long term holders. Sadly I think concerns about the Budget has caused some of them to reduce. I have a medium size holding, have not sold any .... and will be looking to add if we see continued weakness. |
Posted at 13/9/2024 11:31 by sharw The problem with this company is that it does not communicate with either the market or its shareholders except when it has to. So, in the last twelve months we have had just two trading statements - the interim and final results.It is obliged to inform the market if its financial situation diverges from brokers' expectations. (Rule of thumb is that it must do so if 10% out). BVXP did this once - on 14/9/22 when it warned that results would be "significantly ahead of market expectations". Results are on Mon 28th October |
Posted at 23/5/2024 08:39 by gsbmba99 “Building on the foundation our team developed last year, Quanterix is entering a new innovation and product delivery phase,” said Masoud Toloue, Chief Executive Officer of Quanterix. “We’ve announced the first of several new assays that could re-define the way Tau is measured from the brain versus peripheral sources. We will continue to lead in bringing novel biomarker detection solutions to market for the research community; developing tests to study and enable the early detection of neuro-pathologies such as Multiple Sclerosis, Parkinson’s, and Alzheimer’s disease.” ( A bit unclear but maybe brain-derived tau?Page 6 of the accompanying results presentation makes it clear Mr. Toloue is indeed talking about Quanterix introducing an assay for brain-derived tau in Q2 ( Could this be a first commercial success for the UGOT/BVXP BD-tau antibody? |
Posted at 25/3/2024 10:39 by melody9999 I see Cavendish have raised their price target to 5900p from 4400p in Oct 23. Will be happy to see the BVXP once again climb above the Cavendish target price! |
Posted at 12/2/2024 12:37 by maddox BVXP are in the running to develop what has been described as the 'Holy Grail' of diagnostic testing - an early stage Alzheimer's test.BBC Radio 4 Today report on new Alzheimer's treatments. Mentions that there are about 28 dementia drugs in late stage development. Whilst the current two leading drugs show efficacy the promise is of better drugs being developed. The need for an early stage diagnostic test is clear in this report. Arguably, it's equally as important to have a simple early stage test as the drugs. |
Posted at 23/1/2024 10:08 by alter ego Can't be certain but it sounds like a BVXP SMA.Sky news report today mentions " Measuring levels of a protein called p-tau217 in the blood...." "The study from Dr Nicholas Ashton at the University of Gothenburg, and colleagues, is published in the Jama Neurology journal." From BVXP Annual Report for year ended 30/6/23 "A leading blood biomarker for “A” is a phosphorylated form of tau called pTau217. A prototype assay from Gothenburg using an SMA has now been established which has performed well with frozen patient samples from a number of different cohorts." and "A novel blood-based prototype assay for neurodegeneration (N) using another Tau SMA has also been developed in Gothenburg. This work clearly supports the potential utility of this blood test and further work is ongoing in Gothenburg with further publications planned." |
Posted at 31/10/2023 09:48 by maddox If you top-up now at our shorted depressed price you'll be locking in a nice yield of c.4%.One further point the 2023 dividends of 152p looks to be no change on 2022. However, the 152p paid in 2022 included one of BVXP's regular special dividends of 26p. So, excluding this the dividends increased a very healthy 20.6%! In the last five years BVXP has paid three Special Dividends - so that 4% is probably understated albeit the corp tax increase will slow cash accumulation. |
Posted at 30/10/2023 10:28 by 74tom @Big7time, 2017 earnings were 96p, so earnings grow has been nowhere near 3x in that time period. At the start of 2017 it was trading at £13.50 so a 1 year forward P/E of around 14x, by the end of 2017 shares had jumped to £25 as the P/E multiple exploded, this was justified as the EPS growth was significant (43% from 2016-2017).Where is the evidence of that EPS growth right now? At 14x it would be valued at £22.40 with a dividend yield of 6.7%, in the current interest rate environment that would make sense & be a more attractive level to invest. I suspect shares derate to somewhere between there and present levels - let's see. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
